We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Commercial Laboratory Now Offers Advanced Genomic Services

By LabMedica International staff writers
Posted on 20 Dec 2010
Clinicians and researchers can take advantage of a newly upgraded genomic services laboratory.

Ambry Genetics (Aliso Viejo, CA, USA) has recently launched their Illumina HiSeq 2000 Next Generation Sequencing Service. More...
This advanced genomic service is based on the Illumina (San Diego, CA, USA) HiSeq 2000 sequencing system, which offers reversible terminator-based sequencing by synthesis chemistry in combination with innovative engineering. The HiSeq 2000 reputedly delivers the industry's highest sequencing output and fastest data generation rate. Its human interaction design features and easy sequencing workflow have set a new standard for simplicity and user experience.

Ambry Genetics has now become a Certified Service Provider (CSPRO) for the Illumina HiSeq 2000. Becoming a certified service provider required completing and passing the rigorous certification program set forth by Illumina. As a CSPRO, Ambry Genetics collaborates with Illumina to ensure the genetic analysis services provided to customers are the highest quality. In this regard, Ambry has built a reputation for service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research.

"We have continued to invest and develop our sequencing operations to become Illumina experts," said Ardy Arianpour, vice president of business development at Ambry Genetics. "All of our customers are excited about the Illumina HiSeq because it expands our whole genome and exome sequencing services to the next level and gives them the opportunity to reduce their costs while providing more data. If Illumina is your preferred platform then we want to be your preferred sequencing provider."

Related Links:
Ambry Genetics
Illumina




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.